# GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer

Source: https://onco.cc/trials/nct06994507/  
OnCo record `nct06994507` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of GM1 in advanced solid tumours, run by Qilu Pharmaceutical Co., Ltd., now recruiting.

## Summary

GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer is a phase 3 interventional study registered as NCT06994507 by Qilu Pharmaceutical Co., Ltd., with 352 participants planned, started 2025-08-01 and due to reach its primary completion in 2026-09. Interventions recorded: GM1 and Placebo.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06994507
- Phase: 3
- Setting: A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 3 Trial of GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast Cancer（Gypsophila )
- Sponsor: Qilu Pharmaceutical Co., Ltd.
- Enrolled: 352

## Sources

- ClinicalTrials.gov NCT06994507: https://clinicaltrials.gov/study/NCT06994507

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)

---
JSON: https://onco.cc/api/v1/entities/nct06994507.json